TWB-103

N/A

Report date: 2022/12/03 23:08:16

Base Information

Drug NameTWB-103

Drug Alias NameTWB-103TWB-103 (live allogenic cell product)

ClassificationCell and gene therapy > Cell therapy > Somatic cell > Dermal fibroblasts therapyCell and gene therapy > Cell therapy > Source of cells > Fetal-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsDiabetic Foot

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesElanix Biotechnologies Easywell Biomedicals Inc

China Registration ClassN/A

Develop Information

Active CompaniesTranswell Biotech Co Ltd

Inactive CompaniesN/A

Active IndicationsDiabetic Foot

Inactive IndicationsN/A

Other Information

ATC CodeN/A